Company Overview
Nautilus Biotechnology, Inc. operates as a development stage life sciences company dedicated to creating platform technology designed to quantify and unlock the complexity of the proteome within the United States. The firm focuses on developing the Nautilus Voyager Platform, an end-to-end solution that encompasses instrumentation and related components for proteomic analysis. This entity functions within the broader Healthcare sector, specifically targeting the Biotechnology industry, a classification that signifies its engagement in the research and development of biological processes and products for medical applications. The company's current scale is reflected by a market capitalization of $494.87M and an employee base of 130 individuals. While the annual revenue figure is not disclosed in the available data, the market cap indicates that the market values the company's intellectual property and platform potential at nearly half a billion dollars, suggesting significant investor interest in its technological capabilities despite the lack of traditional revenue metrics typically seen in mature biotechnology firms.
Financial Health
The financial statements for the trailing twelve months show revenue figures marked as unavailable, with a reported net income of $-59,001,000 and an EBITDA of $-65,084,000. The substantial gap between the zero revenue figure and the negative net income of $-59,001,000 reveals a cost structure dominated by high operational expenditures, likely driven by research and development activities and platform development costs rather than commercial sales. The company reports a free cash flow of $-28,780,124, which indicates a consumption of cash reserves necessary to fund its development-stage operations and ongoing scientific research. Analysis of the three key margin metrics shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, each indicating that the company has not yet achieved profitability from its core operations or sales activities. Regarding liquidity, the company holds $103.41M in cash against $30.02M in debt, resulting in a debt-to-equity ratio of 19.12. This high debt-to-equity ratio suggests a leveraged balance sheet where equity is significantly smaller than total debt obligations, a common characteristic for early-stage biotechnology companies relying on debt financing or capital markets. However, the current ratio stands at 13.32, which indicates a very strong position in short-term liquidity relative to short-term obligations, providing ample buffer to meet immediate financial commitments. The return on equity is reported at -32.3% and the return on assets at -19.3%, metrics that reveal that management is currently generating negative returns on the capital deployed, a typical scenario for companies in the development phase that have not yet transitioned to generating positive earnings.
Valuation Assessment
The valuation metrics present a complex picture with a trailing P/E ratio listed as N/A and a forward P/E of -5.28. The negative forward P/E implies that the market expects earnings to remain negative or for the company to incur further losses in the near term, preventing a traditional price-to-earnings multiple from forming. The price-to-book ratio is 3.15, which indicates that the market is valuing the company at more than three times its net asset value, suggesting a premium placed on its intangible assets and future platform potential rather than current book value. Alternative valuation metrics include a price-to-sales ratio of N/A and an EV/EBITDA of -6.48, both of which suggest that traditional valuation multiples are not applicable due to the absence of positive earnings and sales data. The stock has traded between a 52-week high of $4.31 and a 52-week low of $0.62. Without a specific current price to calculate the exact percentage, the range demonstrates extreme volatility, with the stock capable of moving from a low of $0.62 to a high of $4.31 within a single year. The beta value is 1.36, which means the stock's price volatility is 36% higher than the broader market, indicating that the share price tends to amplify market movements significantly more than large-cap stocks.
Growth & Income
The available facts indicate that revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, as the company has not yet established a consistent history of positive revenue or earnings growth. Consequently, the concept of earnings growing faster or slower than revenue is not currently applicable as both metrics are undefined or negative. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all available cash flow to reinvest into its platform development rather than distributing income to shareholders. This reinvestment strategy is standard for development-stage life sciences companies that prioritize funding research and product development over providing current income to investors. The overall growth and income profile for Nautilus Biotechnology, Inc. is characterized by a complete absence of current income generation and historical growth rates, with all financial focus directed toward achieving commercial viability for the Nautilus Voyager Platform in the future.